MRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1552-1556

  Wei, Jia ^a,b   Costa, Carlota ^c   Ding, Yitao ^a,b   Zou, Zhengyun ^a,b   Yu, Lixia ^a,b   Sanchez, Jose Javier ^d   Qian, Xiaoping ^a,b   Chen, Hong ^a,b   Gimenez Capitan, Ana ^c   Meng, Fanqing ^a   Moran, Teresa ^c,e   Benlloch, Susana ^c   Taron, Miquel ^e   Rosell, Rafael ^c,e   Liu, Baorui ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c INSTITUT UNIVERSITARI DEXEUS   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; OXALIPLATIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN PIAS 1; PROTEIN PIAS 4; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DNA REPAIR; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SIGNET RING CELL; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROTEIN INHIBITORS OF ACTIVATED STAT; RETROSPECTIVE STUDIES; RNA, MESSENGER; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; STOMACH NEOPLASMS; TAXOIDS;

EID: 80054915400     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr326     Document Type: Article

References (28)

1. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909. (Pubitemid 46630593)
2. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-1442.
3. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92(9):1644-1649. (Pubitemid 40762627)
4. Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer. 2005;93(2):190-194. (Pubitemid 41135888)
5. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 2009;10(9):903-912.
6. Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. 2009;12(3):132-141.
7. Christophorou MA, Ringshausen I, Finch AJ, et al. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006;443(7108):214-217. (Pubitemid 44387609)
8. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160-1166. (Pubitemid 46877472)
9. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28(5):739-745. (Pubitemid 350217064)
10. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63(19):6221-6228. (Pubitemid 37255167)
11. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13(24):7413-7420.
12. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13(20):2443- 2449. (Pubitemid 39377848)
13. Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One. 2008;3(11):e3695.
14. Margeli M, Cirauqui B, Castella E, et al. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One. 2010;5(3):e9499.
15. Font A, Taron M, Gagg JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011;22(1):139-144.
16. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 2008;68(2):605-614. (Pubitemid 351380090)
17. Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008;8:97.
18. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One. 2009; 4(5):e5133.
19. Sobhian B, Shao G, Lilli DR, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science. 2007;316(5828): 1198-1202. (Pubitemid 46877483)
20. Morris JR, Boutell C, Keppler M, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature. 2009;462(7275):886- 890.
21. Galanty Y, Belotserkovskaya R, Coates J, et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature. 2009;462(7275):935-939.
22. Morris JR. SUMO in the mammalian response to DNA damage. Biochem Soc Trans. 2010; 38(pt 1):92-97.
23. Morris JR. More modifiers move on DNA damage. Cancer Res. 2010;70(10): 3861-3863.
24. Greene F, Page D, Fleming I, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
25. Lee ET, Wang JW. Statistical Methods for Survival Data Analysis. Hoboken, NJ: John Wiley & Sons; 2003.
26. Crowley J, Ankerst DP. Handbook of Statistics in Clinical Oncology. New York, Marcel-Dekker and Chapman & Hall; 2006.
27. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655. (Pubitemid 13149996)
28. Weberpals J, Garbuio K, O'Brien A, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer. 2009;124(4):806-815.